↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Cannon Christopher P.) ;srt2:(2010-2014)"

Sökning: WFRF:(Cannon Christopher P.) > (2010-2014)

Resultat 31-33 av 33

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
31.	Wallentin, Lars, et al. (författare) No misrepresentation of vital status follow-up in PLATO : Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial : Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014 2014 Ingår i: International Journal of Cardiology. - : Elsevier BV. - 0167-5273 .- 1874-1754. ; 176:1, s. 300-302 Tidskriftsartikel (refereegranskat)
32.	Wallentin, Lars, et al. (författare) Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome Commentary on : DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013 2014 Ingår i: International Journal of Cardiology. - : Elsevier BV. - 0167-5273 .- 1874-1754. ; 170:3, s. E59-E62 Tidskriftsartikel (refereegranskat)
33.	White, Harvey, et al. (författare) Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease 2010 Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 160:4, s. 655-661.e2 Tidskriftsartikel (refereegranskat)abstract Background Elevated plasma levels of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) are associated with increased risk of cardiovascular (CV) events. Direct inhibition of this proinflammatory enzyme with darapladib may benefit CV patients when given as an adjunct to standard of care, including lipid-lowering and antiplatelet therapies. Methods STABILITY is a randomized, placebo-controlled, double-blind, international, multicenter, event-driven trial. The study has randomized 15,828 patients with chronic coronary heart disease (CHD) receiving standard of care to darapladib enteric-coated (EC) tablets, 160 mg or placebo. Results The primary end point is the composite of major adverse cardiovascular events (MACE): CV death, nonfatal myocardial infarction, and nonfatal stroke. The key secondary end points will include major coronary events, total coronary events, individual components of MACE, and all-cause mortality. Prespecified substudies include 24-hour ambulatory blood pressure monitoring, albuminuria progression, changes in cognitive function, and pharmacokinetic and biomarker analyses. Health economic outcomes and characterization of baseline lifestyle risk factors also will be assessed. The study will continue until 1,500 primary end points have occurred to achieve 90% power to detect a 15.5% reduction in the primary end point. The median treatment duration is anticipated to be 2.75 years. Conclusions STABILITY will assess whether direct inhibition of Lp-PLA(2) with darapladib added to the standard of care confers clinical benefit to patients with CHD.

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 31-33 av 33

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (33)

Typ av innehåll: refereegranskat (31); övrigt vetenskapligt/konstnärligt (2)

Författare/redaktör: Cannon, Christopher ... (31); Storey, Robert F. (25); Wallentin, Lars (24); Harrington, Robert A (20); Husted, Steen (20); Becker, Richard C. (17); visa fler...; James, Stefan K (12); Steg, Philippe Gabri ... (10); Mahaffey, Kenneth W. (10); James, Stefan (8); Held, Claes (8); Himmelmann, Anders (7); Steg, Ph Gabriel (6); Wallentin, Lars, 194 ... (6); Held, Claes, 1956- (5); Emanuelsson, Håkan (5); Cornel, Jan H. (5); Angiolillo, Dominick ... (5); Katus, Hugo A (4); James, Stefan K., 19 ... (4); Morais, Joao (4); Varenhorst, Christop ... (4); Siegbahn, Agneta (3); Wojdyla, Daniel (3); Cools, Frank (3); Lewis, Basil S. (3); Pais, Prem (3); de Winter, Robbert J ... (3); Wernroth, Lisa (2); Sabatine, Marc S (2); Lindholm, Daniel (2); Armstrong, Paul W. (2); Granger, Christopher ... (2); Wojdyla, Daniel M. (2); Vinereanu, Dragos (2); Goodman, Shaun G. (2); Lopez-Sendon, Jose (2); Ruda, Mikhail (2); Aylward, Philip (2); Keltai, Matyas (2); Parkhomenko, Alexand ... (2); Diaz, Rafael (2); White, Harvey D. (2); Stevens, Susanna R. (2); Smith, Peter (2); Chen, Hong (2); Alström, Ulrica (2); Giannitsis, Evangelo ... (2); Avezum, Alvaro (2); Aylward, Philip E. (2); visa färre...

Lärosäte: Uppsala universitet (32); Karolinska Institutet (2); Göteborgs universitet (1); Umeå universitet (1); Stockholms universitet (1); Linköpings universitet (1); visa fler...; Lunds universitet (1); visa färre...

Språk: Engelska (33)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (12); Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy